Info

Biomedical Frontiers is a privately held biopharmaceutical company developing a family of novel and proprietary iron-binding drugs for the treatment of a number of medical indications, including iron overload disorders, iron poisoning and diabetic neuropathy. BMF has been granted Orphan Drug Designations for its 40SD02 drug for treatment of iron poisoning and for treatment of iron overload, resulting from chronic transfusion therapy in diseases such as thalassemia and sickle cell anemia.